MTOR and non-small cell lung carcinoma: The results align with the central role of the PI3K/AKT/mTOR pathway in NSCLC and support therapeutic strategies that restore PIK3R1 function or inhibit downstream signaling in LUAD preclinical and clinical studies [96].